Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721535 | 0.86 | PKM (0.58) | KDM4EHPGDSMN1; SMN2KCNH2PKM | |
| SCHEMBL11099277 | 0.86 | MCL1 (0.70) | MCL1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL718499 | 0.85 | MAPT (0.57) | MCL1KDM4EALDH1A1SMN1; SMN2PKM | |
| SCHEMBL720540 | 0.80 | HTT (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2KCNH2 | |
| SCHEMBL13102716 | 0.79 | KDM4E (0.60) | MCL1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11686876 | 0.78 | MCL1 (0.77) | MCL1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14648196 | 0.78 | MCL1 (0.77) | MCL1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4615856 | 0.78 | MCL1 (1.00) | MCL1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4653953 | 0.78 | KDM4E (0.49) | MCL1KDM4EALDH1A1HPGDPKM | |
| SCHEMBL716858 | 0.77 | KDM4E (0.48) | MCL1KDM4EALDH1A1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926332-B2 | Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | EGIS GYOGYSZERGYAR ZRT. (HU) | 2018-03-27 | — | — | US | disclosed |
| US-20170002020-A1 | NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM | EGIS GYOGYSZERGYAR ZRT. (HU) | 2017-01-05 | — | — | US | disclosed |
| EP-3097110-A1 | NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Egis Gyógyszergyár Zrt. (HU) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015110848-A1 | NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2015-07-30 | — | — | WO | disclosed |
| US-8778932-B2 | Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| EP-2497774-B1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB (FR) | 2013-10-16 | — | — | EP | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2012120206-A1 | NOVEL DIHYDRO-OXAZOLOBENZODIAZEPINONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EGIS GYOGYSZERGYAR NYRT (HU) | 2012-09-13 | — | — | US | disclosed |
| EP-2497774-A1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | Les Laboratoires Servier (FR) | 2012-09-12 | — | — | EP | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MCL1 900/4885KDM4E 1907/4885ALDH1A1 504/4885 |
| US-20170002020-A1 | NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM | GABRB2, GABRB3, GABRA5 | MCL1 2485/4885KDM4E 1713/4885ALDH1A1 603/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MCL1 900/4885KDM4E 1907/4885ALDH1A1 504/4885 |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GRIN2C, GRIN2B, GRIN2A | MCL1 3565/4885KDM4E 2486/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.